Detalhe da pesquisa
1.
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).
Br J Cancer
; 127(6): 1051-1060, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35739300
2.
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
BMC Cancer
; 21(1): 1238, 2021 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34794412
3.
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
BMC Cancer
; 20(1): 670, 2020 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680483
4.
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
BMC Med
; 17(1): 182, 2019 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31578141
5.
Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
World J Urol
; 36(3): 417-425, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29256020
6.
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Lancet Oncol
; 17(3): 378-388, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26794930
7.
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 17(11): 1599-1611, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27720136
8.
An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.
Hum Mol Genet
; 23(22): 5976-88, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24969085
9.
Medical treatment of renal cancer: new horizons.
Br J Cancer
; 115(5): 505-16, 2016 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27490806
10.
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.
Oncologist
; 20(9): 1028-35, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26240132
11.
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Genes Chromosomes Cancer
; 53(1): 38-51, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24166983
12.
Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.
Curr Oncol Rep
; 16(2): 370, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24445502
13.
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
Lancet Oncol
; 14(7): 619-26, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23680111
14.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Invest New Drugs
; 31(5): 1283-93, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23625328
15.
Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.
Curr Oncol Rep
; 15(2): 91-7, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23334510
16.
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD.
PLoS Genet
; 6(8)2010 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20700436
17.
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Lancet Oncol
; 13(10): 1055-62, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22959186
18.
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
J Urol
; 188(6): 2095-100, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23083849
19.
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.
Invest New Drugs
; 30(1): 341-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20683637
20.
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
J Clin Oncol
; 40(16): 1772-1782, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35213214